
MONDAY, Nov. 13, 2023 (Healthday News) — In a finding that could change the landscape of heart disease care, the wildly popular weight-loss drug Wegovy has proved its mettle in protecting the heart after lowering the risk of cardiac problems in patients by 20%. The results from this large, international study had been eagerly awaited by scientists and doctors alike. Why? It is the first to show that Wegovy’s therapeutic powers may extend to the cardiovascular system, helping prevent a heart attack, stroke or a heart-related death in people who already have heart disease but not diabetes. “It moves from a kind of therapy that reduces body weight to a therapy that reduces cardiovascular events,” study author Dr. Michael Lincoff, vice chairman for research in the department of cardiovascular medicine at the Cleveland Clinic, told the Associated Press. A high-dose version of the diabetes drug Ozempic, which already has been shown to lower the risk of heart problems in people who have diabetes, Wegovy seems to do the same for heart patients who don’t have the blood sugar disease. Dr. Francisco Lopez-Jimenez, a heart expert at the Mayo Clinic, told the AP that he believes the new findings will alter heart treatment guidelines and “dominate the conversation” for years to come. “This is the population who needs the medicine the most,” said Lopez-Jimenez, who wasn’t… read on > read on >